5247422025-01-012025-03-315247422025-03-315247422024-03-315247422024-04-012025-03-315247422025-01-012025-03-31in-capmkt:OtherExpenses1Member5247422024-04-012025-03-31in-capmkt:OtherExpenses1Member5247422025-01-012025-03-31in-capmkt:ReportableSegments1Member5247422025-01-012025-03-31in-capmkt:ReportableSegments2Member5247422025-01-012025-03-31in-capmkt:ReportableSegments3Member5247422024-04-012025-03-31in-capmkt:ReportableSegments1Member5247422024-04-012025-03-31in-capmkt:ReportableSegments2Member5247422024-04-012025-03-31in-capmkt:ReportableSegments3Member5247422025-01-012025-03-31in-capmkt:ReportableSegments1Member5247422025-01-012025-03-31in-capmkt:ReportableSegments2Member5247422025-01-012025-03-31in-capmkt:ReportableSegments3Member5247422024-04-012025-03-31in-capmkt:ReportableSegments1Member5247422024-04-012025-03-31in-capmkt:ReportableSegments2Member5247422024-04-012025-03-31in-capmkt:ReportableSegments3Member5247422025-01-012025-03-31in-capmkt:ReportableSegments1Member5247422025-03-31in-capmkt:ReportableSegments1Member5247422025-01-012025-03-31in-capmkt:ReportableSegments2Member5247422025-03-31in-capmkt:ReportableSegments2Member5247422025-01-012025-03-31in-capmkt:ReportableSegments3Member5247422025-03-31in-capmkt:ReportableSegments3Member5247422025-01-012025-03-31in-capmkt:ReportableSegments1Member5247422025-03-31in-capmkt:ReportableSegments1Member5247422025-01-012025-03-31in-capmkt:ReportableSegments2Member5247422025-03-31in-capmkt:ReportableSegments2Member5247422025-01-012025-03-31in-capmkt:ReportableSegments3Member5247422025-03-31in-capmkt:ReportableSegments3Member5247422025-01-012025-03-31ItemsThatWillNotBeReclassifiedToProfitAndLoss15247422025-01-012025-03-31ItemsThatWillNotBeReclassifiedToProfitAndLoss25247422024-04-012025-03-31ItemsThatWillNotBeReclassifiedToProfitAndLoss15247422024-04-012025-03-31ItemsThatWillNotBeReclassifiedToProfitAndLoss25247422025-01-012025-03-31ItemsThatWillBeReclassifiedToProfitAndLoss15247422024-04-012025-03-31ItemsThatWillBeReclassifiedToProfitAndLoss15247422025-01-012025-03-31AuditorDomain1iso4217:INRxbrli:pureiso4217:INRxbrli:shares524742CAPLIPOINTNOTLISTEDINE475E01026CAPLIN POINT LABORATORIES LIMITEDMain BoardEquity2024-04-012025-03-312025-05-152025-05-07INRCroresQuarterlyFourth quarterGeographical2025-05-1511:45:002025-05-1513:10:00trueCash Flow IndirectDeclaration of unmodified opinion2025-01-012025-03-31AuditedConsolidated502450000025740000052819000006084000001387700000159000004651000001700000170400000866800000351600000017659000000176590000029270000021200000313900000014520000000008000001452800000-175000001435300000140820000027100000152000000218.7518.690018.7518.690001. The above Audited Consolidated Financial Results for the Quarter and Year ended March 31 2025 have been recommended by the Audit Committee and have been approved by the Board of Directors of the Company at their respective meetings held on May 15 2025. <BR> <BR> 2. The Audited Consolidated Financial Results of the Company has been prepared in accordance with the Indian Accounting Standards prescribed under Section 133 of the Companies Act, 2013 the Act read with relevant rules issued thereunder Ind AS and other accounting principles generally accepted in India and in terms of Regulation 33 of the SEBI Listing Obligations and Disclosure Requirements Regulations 2015. <BR> <BR> 3. The Group has identified two geographical segments as its reportable segments in accordance with Ind AS 108 Operating Segments. Segment 1 Rest of the World Segment 2 United States of America USA Accordingly segment reporting has been presented along with the results on the above basis. <BR> <BR> 4. During the quarter and year ended March 31 2025 the Company has allotted NIL equity shares and 69950 equity shares of Rs. 2 each under the Employees Stock Option Schemes respectively and the total number of equity shares of the Company stands at 76011696 as at March 31 2025 and 75941746 as at March 31 2024. The Company had allotted NIL shares and 39000 shares during the quarter ended and year ended March 31 2024 respectively <BR> <BR> 5. As regards the pending Insurance claim legal proceedings have been initiated with appropriate legal forum to pursue a full settlement of its rightful claim arising from flood related damages along with other related claims by Caplin Steriles Limited CSL Subsidiary Company. CSL remains confident of a favourable outcome in the ongoing litigation and accordingly continues to recognize the insurance claim as recoverable. <BR> <BR> 6. The Consolidated Results for the year ended March 31 2025 presented above have been audited by the Statutory Auditors of the Company. <BR> <BR> 7. The Board of Directors at their meeting held on May 15 2025 approved an interim dividend of Rs.3.00 150% per equity share of Rs. 2 each for the Financial Year 2024 25. <BR> <BR> 8. The figures for the quarter ended March 31 2025 and March 31 2024 are balancing figures between the audited figures in respect of full financial year and the published year to date figures upto the third quarter of the relevant financial year which have been subjected to limited review by the Statutory Auditors. <BR> <BR> 9.Previous periods figures have been regrouped reclassified to be in conformity with current periods classification disclosure wherever necessary.2024-04-012025-03-31AuditedConsolidated193747000009643000002033900000024845000005757000000-533100000177720000061000006596000003419800000135711000006767900000067679000001253300000103600000135690000005411000000000-100000541090000027070000056816000005633800000478000001520000002070.5770.250070.5770.25000Other Expenses866800000Other Expenses34198000005303200000139220000000112700000428000000027913000000279130000011041000001074630000033610000003113300000632490000019945000003919600000057370000015926000000205250000021339500000320858000001520000002835290000028504900000359000000288639000000000291000002910000013200000760000010820000015810000055000002280000021530000002175800000452500000263380000019000000024000000000306380000000322190000032085800000Rest of the World4061200000USA963300000Unallocated257400000Rest of the World15829600000USA3545100000Unallocated96430000052819000002033900000000528190000020339000000Rest of the World1354700000USA154600000Unallocated0Rest of the World5403400000USA400100000Unallocated015093000005803500000-257400000-96430000017667000006767800000Rest of the World14489800000USA5800900000Unallocated0202907000001179510000032085800000Rest of the World2689100000USA532800000Unallocated03221900000032219000006100000269400000-8775000000-54330000000-234000000-28810000000065960000000000-3460000006364000000-5010000003760000003425000000-1138200000562970000000013060000000432370000000021375000000000019152000000000000000000000005172000000188200000-33473000000000001000000270000000379900000610000000-383200000593200000059320000013870000001980200000Remeasurements of Defined Benefit Plan-2800000Income tax relating to these items700000-2100000Remeasurements of Defined Benefit Plan1400000Income tax relating to these items-400000100000000Exchange difference in translating the financial statements of foreign operations-15400000-15400000Exchange difference in translating the financial statements of foreign operations26970000026970000000-17500000270700000AuditedtrueBrahmayya & Co.true2027-04-30